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HYBRID MODEL OF ERYTHROPOIESIS AND LEUKEMIA
TREATMENT WITH CYTOSINE ARABINOSIDE
POLINA KURBATOVA∗, SAMUEL BERNARD†, NIKOLAI BESSONOV‡ , FABIEN
CRAUSTE§ , IVAN DEMIN¶, CHARLES DUMONTET‖, STEPHAN FISCHER∗∗, AND
VITALY VOLPERT††
Abstract. A hybrid model of cell population dynamics, where cells are discrete elements whose
dynamics depend on continuous intracellular and extracellular processes, is developed to simulate
the evolution of immature red blood cells in the bone marrow. Cell differentiation, self-renewal
or apoptosis are determined by an intracellular network, based on two proteins, Erk and Fas, and
described by ordinary differential equations, and by local extracellular regulation performed by Fas-
ligand, a protein produced by mature cells whose concentration evolution is represented by a partial
differential equation. The model is used to study normal and leukemic red blood cell production
(erythropoiesis), and treatment of leukemia. Normal cells are assumed to have a circadian rhythm
that influences their cell cycle progression, whereas leukemic cells, are assumed to escape circadian
rhythms. We consider a treatment based on periodic administration of Ara-C, an anti-cancer agent
targeting cells in DNA synthesis. A detailed pharmacodynamic/pharmacokinetic model of Ara-C is
proposed and used to simulate the treatment. Influence of the period of the treatment and the day
delivery time on the outcome of the treatment is investigated and stress the relevance of considering
chronotherapeutic treatments to treat leukemia.
Key words. Hybrid model, leukemia treatment, chronotherapy, regulatory networks, cell cycle
AMS subject classifications. 92C30, 92C37, 92C50, 70F40, 68U20, 35Q70, 35Q92
1. Introduction.
1.1. Regulation of normal erythropoiesis. Erythropoiesis is a part of hemat-
opoiesis, the process regulating blood cell production, and is responsible for red blood
cell formation. Erythropoiesis occurs in discrete anatomic units of bone marrow, the
erythroblastic islands. Erythroblastic islands consist of inner layers of erythroid pro-
genitors and outer layers of erythroblasts organized around one or two macrophages,
which promote erythroblast proliferation [11]. Erythroid progenitors, immature blood
cells with abilities to proliferate and differentiate, divide to produce erythroblasts (ma-
ture progenitors), then reticulocytes (precursor cells) and finally mature erythrocytes
(red blood cells), which leave the bone marrow and enter the blood flow.
Erythropoiesis is a robust system, able to keep and quickly restore an optimal
number of circulating red blood cells even after pertubations e.g. after an injury. Inter-
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nal and external regulations form complex positive and negative regulation pathways
that maintain the integrity of the erythropoietic system [14, 15, 16, 20]. The hormone
erythropoietin (Epo) acts on erythroid progenitors by promoting proliferation and
cell differentiation, and by protecting cells from apoptosis [28]. Its anti-apoptotic ef-
fect is balanced by cell-cell interaction, during which binding of reticulocyte-produced
Fas-ligand to the membrane protein Fas stimulate apoptosis of immature erythroid
progenitors [19]. Fas also induces differentiation, while Erk protein kinase induces
erythroid progenitor self-renewal.
1.2. Treatment of acute myeloid leukemia with Ara-C. Leukaemia is a
malignant disease characterized by abnormal proliferation of immature blood cells or
haematopoietic stem cells within the bonne marrow. There are four types of leukemia:
myelogenous and lymphocytic (according to the haematopoietic lineage involved in
the disease), each of which being acute (rapid increase of immature blood cells) or
chronic (excessive production of relatively mature blood cells). Erythroleukemia is one
of the the eight subtypes of acute myeloid leukemia (AML). It was first described by
Di Guglielmo in the early twentieth century [30], it is characterized by a proliferation
of erythroid and myeloid (white cells) progenitors, and sometimes a pure erythroid
proliferation is observed [27]. A dysfunction of the Epo-mediated apoptosis has been
stressed to be a causative agent of erythroleukemia. Self-activation of Epo-receptors
at the surface of erythroid progenitors [18] could explain the sudden proliferation
of immature erythroid cells. Yet, experiments conducted by [29] indicate that au-
tocrine stimulation by erythropoietin in mice could result in intense proliferation of
erythroid progenitors but never triggered erythroleukemia. Self-activation of Epo-
receptors cannot explain the appearance of erythroleukemia without destabilisation
of other signaling pathways.
During the past decade the first line therapy for AML patients has been daunoru-
bicin or idarubicin in combination with cytosine arabinoside (Ara-C), although new
investigational options exist [23]. Ara-C is characterized by a short half-life and
targets cells during DNA synthesis (S-phase of the cell cycle). After intravenous ad-
ministration, the drug is rapidly metabolized, by deamination in the liver and kidney,
to its inactive form uracil arabinoside (Ara-U). When in the bone marrow, it pen-
etrates proliferating cells membrane and it can be transformed into its active form
arabinoside triphosphate (Ara-CTP), which participates in the DNA duplication, re-
placing natural nucleotides. When the proportion of Ara-CTP in the DNA becomes
sufficiently high, the cell dies by apoptosis.
Ara-C acts on all proliferating cells whether they are leukemic or normal. There-
fore, the aim in optimizing drug administration schedule is to increase cytotoxicity for
leukemic cells and tolerance for normal cells. One possible approach to this problem is
based on chronotherapy, in which drug administration is varied in time (chronomod-
ulated) to exploit the small differences in the temporal organisation of the cell cycle
between normal and leukemic cells.
Erythroid progenitors show specific daily variation in their DNA synthesis activ-
ity. 24 hours studies of healthy bone marrow cells showed circadian (about 24 h)
rhythms in proliferative activity [38]. On an average, the percentage of total bone
marrow cells in DNA synthesis phase is greater at midday than at midnight. Myeloid
and erythroid precursor cells display a daily peak in S-phase at 1 p.m. [39]. In con-
trast, leukemic cells display reduced rhythmicity, or even be arrhythmic [40]. This
difference between healthy and leukemic cells allows could be exploited to reach a
maximal efficacy and minimal toxicity by treating patients at specific times of the
TREATMENT OF LEUKEMIA WITH ARA-C 3
day. This strategy, termed chronotherapy, aims at decreasing toxicity and improv-
ing efficacy of the treatment by synchronizing drug delivery with biological rhythms
[1, 32].
We present here a hybrid model with off-lattice cell dynamics that describes ery-
thropoiesis to explore the interplay between extracellular and intracellular regulation
for the normal and leukemic red blood cell formation. The model is hybrid in the
sense that cells are modeled as discrete objects, while the extracellular space is con-
tinuous. We take a particular care in describing the erythroblastic island, which is
thought to be important for erythropoiesis in vivo, and the effect of cell-cell interac-
tion on cell fate decision. In the hybrid model, cell fate emerges from the intracellular
state of each individual cells. This allows a much finer and more complex regulation,
closer to the biology, and takes into account the heterogeneous and stochastic nature
of cell fate. In contrast to standard macroscopic population models, the rates of self-
renewal, differentiation and apoptosis are not imposed by the model, but are obtained
as a result of intracellular events that are specific to erythropoiesis. In Section 2, we
introduce the hybrid model. In Section 3, we use the hybrid model to simulate the
dynamics of normal and leukemic erythroblastic islands to find out improved adminis-
tration schedules of the cell cycle phase-specific drug Ara-C. We also compare results
of simulations with clinical data on treatment of leukemic haematopoiesis. In Section
4, we discuss biological and computational issues.
2. Mathematical model and methods.
2.1. Hybrid models. We present in this section a hybrid model of erythro-
poiesis with off-lattice cell dynamics [5, 6, 7, 8, 9, 10, 22, 34]. In this approach, cells
are modelled as discrete objects in the two-dimensional space. They interact with
each other and with the surrounding medium mechanically and biochemically [17].
Cells have the ability to move, grow, divide, differentiate and die by apoptosis. The
fate of each cell is determined by intracellular and extracellular regulatory networks.
Intracellular regulatory networks are described by ordinary differential equations:
dui(t)
dt
= F (ui(t), u(xi, t)), (2.1)
where ui is a vector of intracellular concentrations of cell i, u is a vector of extra-
cellular concentrations, F is a vector of reaction rates which is specified for each
particular application. Intracellular concentrations ui are supposed to be uniformly
distributed inside the ith cell. Therefore these functions depend on time t and they
are independent of the space variable x. Values of intracellular concentrations can be
different in different cells. At the same time, they can be influenced by extracellular
concentrations u(x, t). We will see below that cell motion will be reduced to motion
of cell centers. The value of the extracellular concentration in the right-hand side of
equation (2.1) is taken at the center xi of the ith cell (see also Figure 2.1).
Extracellular concentrations [35] are described by reaction-diffusion equations:
∂u
∂t
= D∆u+G(u, ρ). (2.2)
The reaction rate G is the rate of consumption or release of different species by cells.
The reaction rate G depends on the local cell density ρ, D is the extracellular diffusion
rate. The numerical resolution of this equation is based on a conventional implicit
finite-difference alternative direction method. A specific feature of this model is that
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Fig. 2.1. Schematic representation of the hybrid model. The square grid shows the numerical
mesh to solve reaction-diffusion equations (2.2). Cell centers move according to equations (2.3).
The force f(dij ) between two cells depends on the distance between their centers (left). Intracellular
concentrations ui(t) inside the ith cell are described by equations (2.1). They can be influenced by
the extracellular concentrations u(x, t) shown schematically as a blue field (center). If a cell dies by
apoptosis, it is removed from the computational domain. If it divides, it increases its area. Cells
grow by doubling their radii before dividing into two cells with a small radius (right).
cells are not necessarily small in comparison with the space step of the numerical
mesh. A local cell concentration ρ is computed as the total cell area inside each
square of the grid.
The mechanical aspects of the model are based on previous work [8, 9], and we
briefly introduce them here. We model cells as elastic balls (compressible) with an
incompressible core. Cell motion is determined by the sum of the mechanical forces
acting on that cell from other cells. Under the assumption of small deformations, we
can express the mechanical contact force acting between them as a function of the
distance between their centers (Figure 2.1 (left)). The force between two particles
centered at xi and xj is given by a function f(dij) of the distance dij between the
centers. Cell motion is described by the displacement of its center by Newton’s second
law:
mx¨i + µmx˙i −
∑
j 6=i
f(dij) = 0, (2.3)
where m is the mass of the cell, the second term in left-hand side describes the
friction due to viscosity of the surrounding medium, the third term is the potential
force between cells. The force between two spherical particles is
f(dij) =


+∞, dij < d0 − 2H1
K
d0 − dij
dij − d0 + 2H1
, dij < d0,
0, dij ≥ d0
(2.4)
where d0 is the sum of cell radii, K is a positive parameter, and H1 is the size of the
outer shell that form the compressible part of the cell. The force between the particles
tends to infinity when dij decreases to d0 − 2H1. The force is repulsive if dij ≥ d0
and is null otherwise.
Intracellular concentrations determine how cells divide, differentiate or die. Par-
ticular cell fate is triggered when the intracellular concentration of some protein ex-
ceeds a threshold. The threshold represents the degree of activation required to trigger
an irreversible cellular response downstream of the regulatory network modelled. In
the numerical model, if a cell dies by apoptosis, it is removed from the computa-
tional domain. In order for a cell to divide, it increases its radius while preserving
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a circular shape during its growth. Here, radius doubles before division (Figure 2.1
(right)). More realistic cell shape can be considered, by taking a∞-shape for instance
[6, 7, 8, 9].
Parameter values of hybrid model are presented in Table 2.1 and valid for all
numerical simulations and all cell populations unless explicitly stated.
2.2. Intracellular and extracellular regulation of normal erythropoiesis.
In this section, we set up and calibrate the hybrid mode described above to the pro-
cess of erythropoiesis. We consider two types of cells, erythroid progenitors and
reticulocytes (Figure 2.2). Reticulocytes produce Fas-ligand that diffuses into the ex-
tracellular matrix and bind to Fas located on the membrane of erythroid progenitors.
Erythroid progenitors also have Epo receptors (EpoR). Epo production depends on
the number of erythrocytes in blood.
Intracellular regulation. We focus our attention on two key intracellular proteins,
Erk and Fas, which are involved in cell fate decision. High Erk levels induce cell
self-renewal, whereas high levels of Fas induce either cell differentiation or apoptosis.
Evolution of the concentrations of these proteins inside an erythroid progenitor is
described by a system of two ordinary differential equations presented in [16],

dEi(t)
dt
= (α(Epo) + βEi(t)
k)(1− Ei(t)) − aEi(t)− bEi(t)Fi(t),
dFi(t)
dt
= γ(FasL)(1− Fi(t))− cEi(t)Fi(t)− dFi(t),
(2.5)
where Ei(t) and Fi(t) are the concentrations of active forms of Erk and Fas, re-
spectively, in cell i (cell numbering is determined by the discrete off-lattice model).
Intracellular concentrations Ei(t) and Fi(t) are assumed to be uniform inside cell
i. The right-hand sides of equations (2.5) depend on extracellular concentration of
Fas-ligand, denoted FasL, and erythropoietin, denoted Epo, at the position of cell i.
Erk activation rate is proportional to the concentration of inactive Erk, (1 −
Ei), where total Erk concentration has been normalized. Erk is activated by two
pathways. Erk activation is self-amplifying through a positive feedback loop formed
by the activation cascade Erk→Raf-1→Mek→Erk (Figure 2.3). This positive loop is
taken into account by the term Eki , with a cooperativity coefficient k = 2. Erk is
also activated by Epo, through the function α. In a similar way, Fas activation by
Fas-ligand is represented by the functionγ. Erk/Fas activity are mutually exclusive.
Active Erk inhibits Fas expression, and Fas activates the Ask-1/JNK/p38 pathway,
which, in turn, inhibits Erk activation (Figure 2.3). Inhibition terms are modelled as
proportional to EiFi. Finally, both Erk and Fas proteins are deactivated with rate
constants a and d.
The rate γ is a function of FasL, with γ(FasL) = γ0+kγFasL. This approxima-
tion is valid when Fas-ligand is low enough not saturate Fas receptors. Extracellular
Epo concentration is physiologically regulated by oxygen levels in circulation. Here,
as we concentrate on modelling the local regulation of erythropoesis, Epo level is
assumed constant and uniformly distributed in the extracellular medium. Thus, the
rate α in (2.5) will be considered as a positive parameter.
A detailed analysis of this system (2.5) is presented in [16, 20], and we briefly
describe its dynamics. System (2.5) has between one and three stationary points
[16], depending on parameter values. Conceptually, different steady states would
correspond to different cell fates. This idea was exploited here and we modelled the
Erk–Fas interaction as a bistable switch. Parameter values were chosen in such a way
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Fig. 2.2. Schematic representation of erythropoiesis. Erythroid progenitors (yellow cells) can
self-renew producing two similar cells, differentiate producing two reticulocytes (blue cells) or die
by apoptosis. Reticulocytes produce Fas-ligand which can promote differentiation and apoptosis
of progenitors. Reticulocytes leave the bone marrow into blood flow where they become mature
erythrocytes. Hormone erythropoietin, whose production rate depends on the number of erythrocytes
in blood, increases the rate of self-renewal of progenitors and decreases their apoptosis.
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Fig. 2.3. Summary of intracellular protein regulatory network that determines erythroid pro-
genitor fate [adapted from Crauste et al. [16], after Rubiolo et al. [37]].
that the system has three steady states, so as to give approximately correct proportion
between self-renewing, differentiating and apoptotic cells and the correct response of
the system to stimulation by the hormones. Values are given in Table 2.1. Bistability
is illustrated in Figure 2.4, where points A and C are stable nodes, and point B is an
unstable saddle. Point A corresponds to high levels of activated Fas and low levels of
activated Erk, whereas point C corresponds to low levels of activated Fas and high
levels of activated Erk. When Erk–Fas concentration approaches point A (high Fas,
low Erk), the cell dies by apoptosis. When Erk–Fas concentration approaches point
C (low Fas, high Erk), the cell divides into two identical daughter cells. If the cell
does not self-renew or die, it differentiate.
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Fig. 2.4. Phase portrait of system (2.5). Dashed and solid curves are the nullclines associated
with the first and the second equations of system (2.5), respectively. Points A, B and C are stationary
points of system (2.5), points A and C are stable nodes, point B is a saddle.
Let us stress out the conditions that determine erythroid progenitor fate. If during
the cell cycle, the value of Erk becomes greater than a given critical value Ec, the
cell self-renews. At the end of the cell cycle, it divides and gives rise to two daughter
cells identical to the mother cell. However, if Fas concentration becomes greater than
a given critical value, Fc, which depends on Epo concentration, the cell immediately
dies by apoptosis. If neither of these conditions is satisfied, the cell differentiates. At
the end of the cell cycle, the cell divides and gives birth to two more mature cells
labeled here as reticulocytes.
Once produced, reticulocyte remain in the computational domain during a time
equal to one cell cycle, during which it produces Fas-ligand. Then it becomes a mature
erythrocyte and enters the bloodstream. In the framework of our model, reticulocytes
that have performed one cell cycle are removed from the computational domain.
The intracellular regulation scheme described above concerns erythroid progen-
itors but not reticulocytes. Indeed, reticulocytes are post-mitotic cells and do not
proliferate. However, reticulocytes produce Fas-ligand, which influences intracellular
regulation of erythroid progenitors (the second equation in system (2.5) depends on
Fas-ligand). For large values of Fas-ligand, trajectories of the system move towards
greater values of Fi and to smaller values of Ei.
Extracellular regulation. Reticulocytes (post-mitotic precusor cells) produce the
protein Fas-ligand, which binds to Fas receptors located on the surface of neigh-
bouring erythroid progenitors, and stimulates apoptosis or differentiation. Fas-ligand
distribution in space is modelled the following reaction-diffusion equation,
∂FasL
∂t
= D∆FasL+W − σFasL, (2.6)
where W is a source term proportional to the local concentration of reticulocytes.
We have chosen a small diffusion coefficient to account for the short-range cell-cell
interaction [12]. Short diffusion means that Fas-ligand influences erythroid progeni-
tors only when they are sufficiently close to reticulocytes, mimicking cell-cell contact
interaction. Parameter values are in Table 2.1.
The source termW in equation (2.6) depends on the spatial distribution of reticu-
locyte. In numerical simulations, the local concentration of reticulocytes is computed
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Fig. 2.5. Erythroblastic island: yellow cells in the center are erythroid progenitors, blue cells
at the border are reticulocytes producing Fas-ligand (in red). The initial cell distribution is on the
left panel, the typical configuration of the island after several cell cycles on the right panel.
as the total cell area in each box of the numerical grid (see Section 2.1). The space-
and time-dependent concentration of Fas-ligand, FasL(x, t), enters the second equa-
tion of the system (2.5) with the value FasL(xi, t), where xi is the center of cell i.
That is, cell i “sees” the FasL local concentration at its center.
Figure 2.5 shows the evolution of an erythroblastic island under regulation of
Fas-ligand (Epo concentration is constant). The left panel represents the initial cell
configuration with immature progenitors inside and more mature reticulocytes out-
side. The right panel shows the typical structure of the island several cell cycles
later. Extracellular Fas-ligand concentration (shown in red color) is higher near retic-
ulocytes. Fas-ligand released by reticulocytes bind to Fas receptors located on the
membrane of nearby erythroid progenitors. This, in turn, stimulates the production
of Fas and, as a consequence, the intracellular concentration of Fas in the progenitor
can be sufficiently high to induce its apoptosis. Progenitors located at some distance
from reticulocytes can have an intermediate value of intracellular Fas, high enough to
prevent Erk from being activated but low enough for the progenitor to survive. Such
cells will preferentially differentiate into reticulocytes. Finally, progenitors located far
from reticulocytes mostly self-renew, due the the antognistic activation of Erk.
A direct consequence of this description is that the evolution of an erythroblastic
island depends on its size and the number of reticulocytes. In a small island, less
progenitors will self-renew and the island will disappear after a couple of cell cycles.
In contrast, if the island is sufficiently large, more progenitors will self-renew and
the island will grow. Typical examples (obtained through 40 simulations, with the
quartiles represented by dashed lines) are shown in Figure 2.6 where upper curves
represent the number of progenitors, lower curves the number of reticulocytes. Figure
2.6a shows normal erythropoiesis with approximately stable number of progenitors.
Although in some simulations cell population vanishes or grows infinitely, the average
number of progenitors across 40 simulations is approximately constant (Figure 2.6a).
2.3. Pharmacokinetics and pharmacodynamics of Ara-C. Cytosine ara-
binoside, or Ara-C, is one of the most common and effective chemotherapeutic agents
against acute myelogenous leukemia. Once introduced intravenously in the organism,
Ara-C penetrates cell membranes by a mechanism based essentially on the human
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Fig. 2.6. Time evolution of cell number in an erythroblastic island. Solid curves indicate means
and dotted lines the quartiles over 40 simulations. Upper curves represent the number of progenitors.
Lower curves represent the number of reticulocytes.
equivibrative nucleoside transporter-1 (hENT1), which can be considered as facilitated
diffusion. This process does not need energy and follows the gradient of concentra-
tion up to the equilibrium between the intracellular and extracellular concentrations
of Ara-C.
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Fig. 2.7. Metabolism of Ara-C. Schematical representation of Ara-C pharmacokinetics: Ara-C
crosses cell membrane, it is phosphorylated becoming Ara-CTP. Ara-CTP is used for DNA replica-
tion instead of nucleotide C. Besides, Ara-C can be transformed in Ara-U. Adapted from Morrison
et al. [33].
Inside cells, part of Ara-C is phosphorylated into its active form, Ara-CTP, which
arrests DNA synthesis and induces cell apoptosis. The rest, about 70% of Ara-C, is
deaminated into its inactive form Ara-U. Ara-CTP, in turn, can be dephosphorylated
back to Ara-C. In order to take into account the intracellular kinetics of Ara-C and
Ara-CTP wa adapted a model from Morrison and colleagues. This model and param-
eter values (given in Table 2.1) were validated against experimental data [33]. We
take into account these three reactions in order to model the intracellular kinetics of
Ara-C and Ara-CTP (Figure 2.7). The phosphorylation rate of Ara-C into Ara-CTP,
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denoted by rp, is given by a Michaelis-Menten equation
rp =
Vk
1 + KmKa
wi
,
where wi is the Ara-C concentration inside the cell i, Km is the Michaelis-Menten
constant, Ka accounts for additional effects and Vk is the kinase activity responsible
for phosphorylation.
Denote by wai the Ara-CTP concentration in the cell i. Ara-CTP dephosphory-
lation rate, rdp, is given by
rdp =
Vdp
1 +
α1Kdp
wa
i
,
with Vdp the enzyme activity responsible for dephosphorylation, α
1 accounts for ad-
ditional effects, Kdp is the Michaelis-Menten constant. The deamination rate rda of
Ara-C follows a similar kinetics,
rda =
Vda
1 + Kda
wi
,
where Vda is the enzyme activity and Kda the Michaelis-Menten constant.
The kinetics of intracellular Ara-C concentration in cell i is then described by the
following equation,
dwi
dt
= k1(w − wi(t))− k2wi(t)− (rp − rdp + rda), (2.7)
where w = w(t) is the time-dependent extracellular concentration of Ara-C, assumed
to be uniformly distributed in the bone marrow. All cells are in contact with Ara-
C. The constant k1 is related to the rate of membrane penetration, k2 accounts for
degradation of Ara-C. There is no extracellular degradation of Ara-C. We reproduce
a chronomodulated treatment protocol where cells are infused in Ara-C for two hours,
then Ara-C is removed (or washed out). This is modelled by setting the extracellular
Ara-C profile w(t) to a constant wT > 0 for two hours after the starting time of
administration, and to zero outside the treatment time. This Ara-C profile is repeated
at fixed intervals T , ranging from 8 to 74 hours. Individual dosages wT are adjusted
as a function of T to keep the total amount of Ara-C delivered constant, i.e. wT /T is
constant. The time of the day of the first treatment is t0. Thus w(t), with time t in
hours, is given by
w(t) =
{
wT if t0 ≤ t mod T ≤ t0 + 2,
0 otherwise.
(2.8)
The balance equation for the intracellular concentration of Ara-CTP is
dwai
dt
= kα(rp − rdp). (2.9)
Ara-CTP exerts a cytotoxic effect on all dividing cells when it gets inserted into
replicating DNA, replacing natural nucleotides. It arrests DNA synthesis and induces
apoptosis. The quantity pi represents the amount of Ara-CTP incorporated into DNA.
TREATMENT OF LEUKEMIA WITH ARA-C 11
0 50 100 150 200 2500
0.2
0.4
0.6
0.8
1
time(hours)
S 
ph
as
e 
fra
ct
io
n
(a) G1max=7 hours
0 50 100 150 200 2500
0.2
0.4
0.6
0.8
1
time(hours)
S 
ph
as
e 
fra
ct
io
n
(b) G1max=3 hours
Fig. 2.8. Proportion of cells in phase S, with G1min = 0.
The rate of Ara-CTP incorporation into replicating DNA follow a linear equation
during the S phase, where it is assumed that DNA is replicated at a constant rate,
dpi
dt
= kβw
a
i , (2.10)
with kβ the rate of insertion of Ara-CTP. We assume that apoptosis is triggered when
the amount of Ara-CTP into DNA reaches a critical value pcr.
2.4. Organization and duration of the cell cycle. The cell cycle proceeds
sequentially through four phases, the G1, S, G2 and M phases. The DNA synthesis
S phase and the mitosis M phase are separated by the G2 phase (for gap) during
which the cell checks for DNA damage and decides whether it progresses to mitosis.
After mitosis, proliferating cells enter the G1 phase, where it grows and wait for
signal to progress through S phase. After mitosis, cells can also enter a quiescent
state, denoted G0, during which cells are non-cycling. The duration of the G0, G1
and G2 phases are controlled by various intracellular and extracellular mechanisms.
Erythroid progenitors are assumed to be continuously cycling, with a non-existent G0
phase, while reticulocytes are in G0 phase. The G1 phase accounts for most of the
cell cycle length variability [36]. We assume that the G1 phase duration is a random
variable with a uniform distribution between G1min and G1max, the minimal and
maximal duration.
From a modelling point of view, variation in the G1 phase duration, and conse-
quently in cell cycle duration, cause cells to desynchronize, i.e. the phase distribution
of cells is constant in time. This is an essential feature for the correct modelling of
Ara-C pharmacodynamics and treatment of leukemia. We ran two simulation of the
complete model, with G1min = 0 and G1max = 3 or 7 hours, with initially synchro-
nized cells. For larger cell cycle variability (G1max = 7 hours), the cell population
desynchronizes and the proportion of cells in S phase becomes almost constant after
approximately 7 cell cycles (Figure 2.8a). For lower cell cycle variability (G1max = 3
hours), the proportion of cells in S phase is strongly oscillating, even after several cell
cycles, and the population is not desynchronized.
2.5. Circadian rhythm in the cell cycle. Circadian rhythms gate the pro-
gression through the cell cycle, and hence modulates the proportion of cells in the S
phase according to the time of day [39]. Therefore, the efficiency of a cell cycle-specific
drug can also depend on time of administration [2]. to describe circadian rhythms,
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Table 2.1
Parameter values (N.U. means “no unit”, min is for “minute”). All simulations use these
parameter values, unless explicitly indicated.
Parameter Value Unit Ref/Comment
Mechanical forces
r0 Cell radius 4 µm
H1 Cell compressible part 2 µm
K Positive parameter 1000 µm.min−2
µ viscosity 10000 min−1
Intracellular regulation [16]
α Epo-dependent Erk activation rate 0.0003472 min−1
k Erk self-activation power 2 N.U.
β Erk self-activation rate 0.05 min−1
a Erk degradation rate 0.004 min−1
b Erk inhibition constant 0.0138 min−1
γ0 Constant Fas activation rate 0 min
−1
kγ Fas-ligand-dependent Fas activation rate 0.0002 min
−1
c Fas inhibition rate 0.00138 min−1
d Fas degradation rate 0.0001 min−1
Ec Erk critical level 0.4 N.U.
Fc Fas critical level 0.2 N.U.
Extracellular regulation
D Fas-ligand diffusion coefficient 1e−5 µm2.min−1 [12]
σ Fas-ligand degradation rate 0.02 min−1
W Source term 0.0001 min−1
Metabolism of AraC [33]
k1 Membrane penetration rate 0.0116 min
−1
k2 Ara-C degradation rate 0 min
−1
Vk Kinase activity 1.28 µM.min
−1
Km Michaelis-Menten constant 27.0 µM
Ka Additional effects constant 16 N.U.
Vdp Enzyme activity 300 µM.min
−1
Kdp Michaelis-Menten constant 900 µM
α1 Additional effects constant 44.4 N.U.
Vda Enzyme activity 16.45 µM.min
−1
Kda Michaelis-Menten constant 1011.7 µM
kα Metabolism constant 0.8 N.U.
kβ Ara-CTP conversion rate 1 N.U.
pcr Critical value of Ara-CTP in DNA 40 µM
wT extracellular Ara-C concentration 10 µM for T = 8 hours
wT = 1.25µM/h× T
Circadian rhythm
cx Constant characterizing the circadian clock 0 N.U. cx = 0.5 if
circadian regulation
θ Phase shift 5 hours
Cell cycle
G1min Minimal duration of phase G1 5 hours
G1max Maximal duration of phase G1 31 hours
S Duration of phase S 10 hours
G2/M Duration of phase G2/M 3 hours
Cell cycle (leukemic haematopoiesis)
G1max Leukemic stem cells 31 hours
G1max proliferative leukemic cells 12 hours
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we introduce a “timer” variable cycD, which is an abstraction of the evolution of
the expression of cyclin D1, a circadian clock-controlled protein, whose activity is
required for cell cycle G1/S transition. When the timer cycD reaches the threshold
value cycDc, the cell enters S phase. The G1 phase consists of a incompressible length
G1min and a variable duration. We label the beginning of the variable length part
of G1 phase tv (for a cell having divided a time G1min earlier), and we prescribe
cycD(tv) = cycDv, where the initial concentration of the protein cycDv is a random
variable uniformly distributed in [0, cycDc].
Since the cyclin D1 corresponding gene is controlled by the circadian rhythm,
cyclin D1 protein expression is determined by the time of the day. This is reflected
in the following equation for the concentration of the protein,
dcycD
dt
= 1 + cx sin(f(t− θ)), (2.11)
where f = 2pi
24
, cx ∈ [0, 1] is the amplitude to mean ratio of the circadian rhythms
and θ is a phase shift chosen to reproduce circadian timing of cell division in humans.
The solution to (2.11) is given by the formula:
cycD(t) = cycD0 + (t− t0) +
cx
f
cos(f(t0 − θ))−
cx
f
cos(f(t− θ)), (2.12)
We set τ = t− t0, where τ is the time spent in the variable length part of G1 phase.
Then we have
cycD(t0 + τ) = cycD0 + τ +
cx
f
cos(f(t0 − θ))−
cx
f
cos(f(t0 + τ − θ)), (2.13)
If, cycD(t0 + τc) = cycDc, the concentration of the protein reaches the G1/S transi-
tion threshold value, and the cell enters the S phase. That way, G1 phase duration
is G1min + τc. The variable duration τc a random variable distributed in [0, τmax]
where τmax = τmax(t0 − θ) is the solution in τ to equation (2.13) with cycD0 = 0.
The maximal value of τc, τmax, depends on the difference between the phase of the
circadian clock and the time at which the cell last divided. In absence of circadian
rhythms (cx = 0), we obtain τmax = cycDc. To remain consistent with the G1 phase
duration in absence of the clock, we set cycDc = G1max −G1min.
2.6. Ara-C treatment applied to leukemic haematopoiesis. When we
study Ara-C treatment of the AML, we first consider the case where leukemic stem
cells self-renew but they cannot differentiate or die by apoptosis (Section 3.2). We
call this model the simplest model of leukemia. In reality, leukemic hematopoiesis
can be more complex. It starts with leukemic stem cells, which possess the property
of self-renewal, followed by partially differentiated leukemic cells, some of them pro-
liferating while some others do not proliferate. The exact organization of leukemic
hematopoiesis may strongly depend on individual patients, and it is very difficult, if
possible, to determine it clinically. Therefore comparison of mathematical modeling
with available clinical data can give some insight on leukemic hematopoiesis. We will
discuss this question in more detail in Section 3.3. We will suggest a model of leukemic
hematopoiesis in order to describe the clinical data presented in [31].
Let us note that various models of tumor stem cells have been proposed, both in
solid tumors and in hematological malignancies such as acute myeloid leukemia. In
our approach we have considered that all leukemic cells, including those that undergo
partial differentiation, originate from a single precursor.
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3. Results. In this section, we run simulations of the hybrid model presented
in Section 2. We simulate the action of Ara-C on two type of erythroblastic islands,
with either normal or leukemic erythroid progenitors. In Section 3.1, we focus on the
effect of treatment on proliferation and survival of normal cells. We investigate the
respective influences of the period of treatment and the starting hour of treatment
with respect to the cell cycle duration. In Section 3.2, we simulate the effect of
a chronomodulated treatment with Ara-C, in the situation where normal cells are
subject to circadian rhythm (cx = 0.5 in (2.13)) whereas leukemic cells do not exhibit
circadian rhythm dependency (cx = 0). In these two cases, the cell population is
first simulated from an initial state until it reaches a satisfactory state, in which the
erythroblastic island is large enough and cells are well mixed, as in the right panel of
Figure 2.5. Consequently, time t = 0 corresponds to the time of the beginning of the
numerical experiments and not as the beginning of erythroblastic island simulations.
In Section 3.3 we simulate leukemic haematopoiesis and its treatment with Ara-C.
3.1. Chronomodulated Ara-C treatment in a non-rhythmic population.
We first consider a population of erythroid cells, composed of two types of cells:
erythroid progenitors and reticulocytes, and apply an Ara-C treatment protocol as
described in Section 2.3. We investigate the relevance of taking cell cycle durations
into account when treating with Ara-C, when the circadian clock is neglected (cx = 0).
We performed numerical simulations of erythroid cell populations with an average
duration of cell cycle equal to 31 hours under Ara-C treatment. We considered three
different administration intervals T = 26, 34 and 64 hours (Figure 3.1a). For each
treatment interval, we corrected the dosage wT so as to keep to total amount of Ara-
C administered constant (constant area under the curve of w(t)). Depending on the
treatment intervals, the cell population can either disappear (Figure 3.1a) or grow
(Figure 3.1b,c). The interval T = 26 hours was most lethal to the cells, while the
interval t = 36 hours was least lethal to the cells. Therefore the growth rate under
periodic Ara-C treatment is not a monotonous with respect to the treatment interval.
Because the cytotoxic effect of Ara-C is related to DNA synthesis, it is expected
that a periodic treatment will partly synchronize the cell population. As a result,
time-periodic drug administration killing cells in the S phase will affect the phase
distribution of subsequent cell generations. This can result in so-called resonance
effect, as discussed in [13, 21]. Resonance theory predicts that when the treatment
period is close to the duration of the cell cycle or its multiples, cell kill is minimised.
This is because cells that are not in the S phase during one administration will be
less likely to be in S phase at subsequent administrations, and are shielded from the
treatment.
To further explore this idea, and to see whether a resonance effect is seen in
the hybrid model, we computed the growth rate of the erythroblastic island under
periodic treatments with periods ranging from T = 20 to 74 hours. The resonance
theory predicts that the growth rate, as a function of T , should show a local maximum
near multiples of the cell cycle length. To test that, we simulated periodic treatment
in two populations with different cell cycle length, the first one with a cell cycle length
of 31.0± 13.0 hours and the second one, 33.5± 15.5 hours. Cell population growth or
decay was approximately exponential, with periodic modulations due to the action of
the treatment. We assumed that cell number evolved as N(t) ∼ C(t)eλt, where λ is
the growth exponent (either positive or negative) and C(t) is a T -periodic function,
and fitted λ (Figure 3.2). As a function of T , λ showed a peak near the cell cycle
length. In the first population (length 31.0 hours), the resonance effect was strong,
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Fig. 3.1. Time evolution of erythroid cell number under treatment with Ara-C, for three dif-
ferent treatment intervals T = 26 hours (a), T = 34 hours (b), and T = 64 hours (c).
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Fig. 3.2. Growth exponent λ as a function of the treatment period T , for two different cell
cycle lengths, 31.0± 13.0 hours (a), and 33.5± 15.5 hours (b).
and λ peaked at around 33.0 hours (Figure 3.2a). In the second one (length 33.5),
λ peaked at around 38.0 hours, but the resonance effect was much less pronounced
(Figure 3.2b). For both populations, peaks at higher multiples of the cell cycle lengths
were almost absent. This is probably due to the fast desynchronization of the cell
cycle in these two populations, whose lengths range between 18.0 and 44.0 hours, and
18.0 and 49 hours respectively. Greater cell cycle variability might also account for
the weaker resonance effect in the second population. Taken together, these results
indicate that resonance is seen in the hybrid model, but that cell cycle variability
reduces it effect on the growth rate.
3.2. Chronomodulated Ara-C treatment in a circadian population. Our
simulation results with the hybrid model confirmed that the search for an optimal
treatment schedule is relevant within the context of erythroid cell populations. The
progenitor population can either grow or decay, depending on the Ara-C treatment
period. Here, we look at the effect the circadian modulation of cell cycle progression
has on the treatment efficacy.
Most cytotoxic drugs used in chemotherapy affect both normal and leukemic
cells. In leukemia, downregulation of circadian clock genes is often observed [40], and
malignant cells can even escape circadian control [41]. Thus, a treatment protocol
based on chronotherapeutic principles could exploit this difference between normal
and leukemic cells to reduce toxicity (chronotolerance) and to increase efficacy (chro-
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Fig. 3.3. Time evolution of the fraction of proliferating cells in S phase, under circadian clock
regulation (cx = 0.5).
noefficacy).
We consider two different populations. The first one consists of erythroid progen-
itors under circadian control (cx = 0.5). Simulations in absence of treatment shows
that circadian control naturally induces temporal synchronization of DNA synthesis
activity (Figure 3.3). The fraction of erythroid progenitors in the S phase is max-
imal around 13:00 and minimal between 0:00 and 01:00, in agreement with clinical
observations [39]. The second population consists of leukemic cells, without circadian
control (cx = 0), and therefore desynchronized.
We first submitted the normal population (circadian clock-regulated) to chro-
nomodulated Ara-C treatments with intervals T ranging from 8.0 to 70.0 hours, and
with first treatment starting at times t0 between 01:00 and 24:00, and looked at the
outcome in terms of growth exponents λ (Figure 3.4). High values of λ were associated
to a good outcome (low toxicity) while low values of λ were associated to bad outcomes
(high toxicity). The most important variations of the outcome as a function of t0, for
fixed T were observed for treatment intervals T = 24 hours (Figure 3.4b, zoom in of
Figure 3.4a) and T = 48 hours (Figure 3.4c, zoom in of Figure 3.4a). Outside these
intervals, the starting delivery time t0 does not appear to modify the outcome of the
simulations, which depend mostly on T (Figure 3.4a). If the interval T is slightly
larger (less, resp.) than 24 hours or 48 hours, the time of first delivery t0 should
be advanced (delayed, resp.) to produce an equivalent outcome. This dependence is
more best expressed at 48 hours (Figure 3.4c), and is consistent with previous results
[4]. The white area between 30 and 40 hours (Figure 3.4a) corresponds to a treatment
interval close to the average duration of the cell cycle. The reason of its appearance
is the same as for the first peak in Figure 3.2a, discussed in the Section 3.1. This
shows that the cell cycle resonance effect can be present even when the cycle cell is
driven by the circadian clock. Taken together, these results show that the circadian
clock influence the treatment outcome when the intervals are close to multiples of
the circadian period. Outside these intervals, the timing (t0) of the treatment has no
effect on the outcome.
We then compared the evolution of cell numbers in the normal population, subject
to the same chronomodulated Ara-C treatment with intervals T = 24 or 48 hours,
treatment times t0 equal to 01:00 or 13:00. The time 01:00 corresponds to the lowest
fraction of cells in the S phase, while 13:00 corresponds to the highest fraction (see
Figure 3.3). Cell number decay was slower when Ara-C was administered at 01:00
compared to 13:00 (Figure 3.5), whether the treatment was administered with 24
TREATMENT OF LEUKEMIA WITH ARA-C 17
1 4 7 10 13 16 19 22
10
20
30
40
50
60
70
treatment time t0 (hours)
pe
rio
d 
(ho
urs
)
 
 
−2.5
−2
−1.5
−1
−0.5
0x 10
−3
(a)
treatment time t0 (hours)
pe
rio
d 
(ho
urs
)
 
 
1 4 7 10 13 16 19 2221
22
23
24
25
26
−8
−6
−4
−2
x 10−4
(b)
1 4 7 10 13 16 19 2245
46
47
48
49
50
treatment time t0 (hours)
pe
rio
d 
(ho
urs
)
 
 
−2.5
−2
−1.5
−1
−0.5
0
x 10−4
(c)
Fig. 3.4. Treatment outcomes for normal cells (cx = 0.5). The gray scale shows the value of
λ as a function of the first day delivery time t0 and the interval T between two consecutive drug
administrations. (a) Growth exponent λ for t0 ranging from 1 a.m. to midnight, and T ranging
between 8 and 65 hours. (b) Specific region around period T=24 hours. (c) Specific region around
period T=48 hours, respectively. All three panels correspond to the same numerical simulations. Low
values of λ indicate bad treatment outcomes (high toxicity, dark regions) and high values indicate
good treatment outcome (low toxicity, light regions).
(Figure 3.5a) or 48 hour-intervals (Figure 3.5b). Decay was slower with treatments at
T = 48 hours than T = 24 hours, independently from t0. Therefore, the best outcome
(less toxicity) is at T = 48 hours with a t0 of 01:00. The worst outcome is at T = 24
hours with a t0 of 13:00.
We finally compared the outcome of normal cells and leukemic cells. We first
assume that the leukemic population has the same properties than the normal one,
except that it is not influence by the circadian clock. All other properties and pa-
rameter values are identical. Populations of normal and leukemic cells were subjected
to a 48 hour-interval treatment at 01:00 or 13:00 (Figure 3.6). The population of
normal cells slowly decays while the population of leukemic cells dies out when t0
is 01:00 (Figure 3.6a). In contrast, the population of normal cells dies much faster
than the population of leukemic cells when t0 is 13:00 (Figure 3.6b). These results
indicate that when treating at multiples of the circadian periods, the exact timing
of administration can decrease Ara-C toxicity in normal cells, while maintaining the
same efficacy against leukemic cells with a fixed set of parameter values (dashed curves
in Figure 3.6a (G1max = 31h) and in Figure 3.6b). However, leukemic cell kinetics
varies between cells and between patients. Varying the value of G1max, we looked at
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Fig. 3.5. Time evolution of the total number of normal cells (cx = 0.5) with Ara-C adminis-
tration at 01:00 (solid lines) or at 13:00 (dashed lines) with a treatment interval T = 24 hours (a),
or T = 48 hours (b).
0 200 400 600 800 100010
0
101
102
103
time(hours)
n
u
m
be
r o
f c
el
ls
 
 
G1max=20
G1max=31
G1max=25
(a)
0 200 400 600 800 100010
0
101
102
103
time(hours)
n
u
m
be
r o
f c
el
ls
 
 
(b)
25 30 35 40 45 50
−1.5
−1
−0.5
0
0.5
1
1.5 x 10
−4
po
pu
la
tio
n 
gr
ow
th
 ra
te
 (λ
)
T
c
(c)
Fig. 3.6. Time evolution of the total number of normal cells ( solid green curve, cx = 0.5) and
leukemic cells ( dashed red curve, cx = 0) with Ara-C administered every 48 hours at 01:00 (a), or
at 13:00 (b). Populations of leukemic cells with different cell cycle length, where G1max is varied,
are presented (a). Growth exponent λ as a function of cell cycle length Tc of leukemic cells (c).
the effect of cell cycle length on the leukemic cell exponent growth for cell cycle length
between 23h and 54h, subject to chronomodulated Ara-C (Figure 3.6c). For cell cycle
length over 46h, λ varies little. For shorter cell cycles, we expected larger values of
λ, but we found instead a minimum at Tc = 28h, due to resonance. Therefore, cell
populations with Tc = 28h (G1max = 25h) decrease faster than cell populations with
Tc = 31h (G1max = 31h), as exemplified in Figure 3.6a. This shows that the efficacy
of the treatment depends in a nonintuitive way on leukemic cell cycle kinetics.
3.3. Comparison with clinical data of leukemic haematopoiesis treat-
ment. In the previous section we considered the simplest model of leukemia where
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leukemic stem cells self-renew but they cannot differentiate or die by apoptosis. More-
over this model does not take into account events occurring between the erythroblastic
islands and the circulation, and does not track the number of circulating cells. Here
we adapt this model to take these events into account and follow the number of circu-
lating cells. This allows us to compare model simulations and clinical data on Ara-C
treatment of leukaemia [31].
The protocol described in [31] was applied to a patient with acute myeloblastic
leukemia who was unresponsive to conventional chemotherapy. Ara-C was adminis-
tered as two hours continuous i.v. infusions for 5 times over a total duration of 34
hr with 6-hr interval between infusions. The number of leukemic cells in blood was
measured every 24 hours.
It appears that these data cannot be described with a single type of leukemic
cells, and more complex leukemic hematopoiesis should be considered. We have tested
different schemes of leukemic hematopoiesis. The minimal model includes leukemic
stem cells (LSC), proliferative leukemic cells and mature leukemic cells (MLC) in
blood. Apoptotic rate of LSCs is assumed to be zero. With probability 0.5, a leukemic
stem cell after its division gives birth to two cells with higher degree of maturity, or to
one LSC and one differentiated cell. These more mature cells, named here proliferative
leukemic cells, represent the second type of cells in the model. Proliferative leukemic
cells at different stages of maturation are also located in the bone marrow. Similar
to LSCs, these cells do not die without medical treatment. After their division, they
give two daughter cells with higher maturity. We assume here seven stages of their
maturity. The cells of eighth stage of maturation form the third type of cells, so
called post mitotic almost mature leukemic cells (MLC), which are released from
the bone marrow into the blood. Parameter values of cell cycle duration for LSCs
and proliferative leukemic cells are given in Table 2.1. The survival half-life of post
mitotic mature leukemic cells in blood was estimated to be about 12 hr [31]. It was
implemented into the model by forcing post mitotic MLC to take a decision every 12
hours to die or to survive with probability 0.5.
We take the pharmacokinetics of medical treatment into account and determine
the number of leukemic cells in blood. In the case of leukemic hematopoiesis described
above, simulations show a good agreement with the clinical data (Figure 3.7, solid
curve). We note that leukemic cells persist in blood for about 60 hours after the
treatment is finished. If we consider a model with only one type of leukemic cells
(LSCs), then we cannot describe this effect because accumulation of leukemic stem
cells in blood at the moment when the treatment is over will not be sufficient to
provide this persistence (Figure 3.7, dashed curve). Including of post mitotic cells is
crucial to achieve a good agreement with the clinical data.
4. Discussion. Erythropoiesis is the process of production and regulation of red
blood cells, which occurs in discrete units of the bone marrow. To understand better
this complex process, we proposed a new multiscale model of erythropoiesis in the
erythroblastic island, based on hybrid discrete-continuous modelling. This approach
takes into account several aspects, including: a) cells as individual objects that can di-
vide, move, change their phenotype (differentiation), die, interact with each other and
with the surrounding medium mechanically [22] and biochemically; b) intracellular
regulatory networks responsible for cell fate, which also include the pharmacokinetics
of medical treatment, described by ordinary differential equations; c) extracellular
biochemical species, whose evolution are described by partial differential equations.
Extracellular regulation includes local regulation due to cell communication in the tis-
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Fig. 3.7. The number of leukemic cells in blood during treatment. Magenta curves represent
numerical simulations. Solid curve corresponds to leukemic haematopoiesis. Dashed curve corre-
sponds to the hybrid model with one type of leukemic cells. Blue points represent the clinical data.
Black intervals signify the time of treatment. 10 µm of Ara-C was given as a 2-hr continuous i.v.
infusion for 5 times over a total duration 34 hr with 6-hr interval between the infusions.
sue and medical aspects such as treatment. Intracellular and extracellular regulations
influence each other in a complex way to determine the fate of each single cells.
We applied this approach to study the treatment of acute myeloblastic leukemia
(AML) with Ara-C, one of the main chemotherapeutic drugs used for AML patients.
We observed a resonance effect in the survival of dividing cells undergoing chronomod-
ulated treatment with phase-specific cytotoxic drugs. Such optimization of treatment
was discussed before in [13, 21], where resonance effect was stronger as a result of low
variability in the cell cycle duration. In vivo resonance effect is difficult to observe,
perhaps due to heterogeneity in cell cycle times. Since Ara-C affects both normal
and leukemic cells, one of the main questions in chemotherapy is to choose an optimal
patient-adapted treatment protocol that allows elimination of most leukemic cells and
preservation of maximum of normal cells. Our results indicate that chronotherapy,
which takes into account circadian rhythms of normal cells, can improve the tolerance
to the treatment.
There are numerous models devoted to modelling of leukemia and its treatment.
However, most of them are population-based model, with little or no heterogeneity
in tumor and host cells [14, 15]. Importance of heterogeneity is evidenced, for in-
stance, by a recent phase III trial for chronotherapy [24], which showed a significant
difference in outcome between women and men, something that was never modeled,
or expected. One way to introduce this difference in a cell population is to take into
account spatial cell distribution: cells differ by their position in space, that is by their
environment (extracellular regulation), and also PK regulation and possibly circadian
clock-regulated PK [3]. It influences intracellular regulation and cell fate. Recently,
Altinok et al. [1, 2] used a cellular automaton to explore the effect of the variability
in the cell cycle length on chronotolerance and chronoefficacy of 5-FU and oxaliplatin.
The model did not account for intracellular regulation which determine cell choice.
A recurring problem with large, detailed models is the question of parameter val-
ues. Here the hybrid model is modular, each module consisting of well defined models,
with their own set of parameters. Pharmacokinetic, cell cycle, regulatory network ki-
netic parameters are known from the literature (Table 2.1). Some parameters are
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not directly available experimentally but we can still find them in order to reproduce
biologically realistic functions of the system, such as correct proportions of each cell
type. Among them are parameters for the intracellular regulation, which were chosen
in order to describe a bistable switch inducing cell decision. Other parameter values
can be identified. For example, θ was identified from the S phase peak at 1 p.m.
The complex, multi-scale aspects of erythropoiesis modelling cannot be taken into
account in simple models. In particular, we should consider spatial distributions of
cells in order to take into account the influence of cell environment on its fate (the
choice between self-renewal, differentiation and apoptosis). Moreover, the size of ery-
throblastic islands can determine their behavior. For instance, with the same values
of parameters, a “small” island can decrease and disappear while a “large” one can
grow. Simpler ODE models with average values of parameters cannot describe this
effect. Continuous models based on partial differential equations can also be used
to describe spatial inhomogeneities. However, continuous models are more difficult
to justify formally than hybrid models. Usually, we first need to formulate a hy-
brid model. After that a continuous model can possibly be derived from it by some
averaging or asymptotic procedure though this step can rarely be rigorously justified.
We note that extracellular regulation is not considered in the model of leukemic
haematopoiesis. There are no extracellular signaling molecules (like Fas-ligand for
erythroid progenitors), which influence cell fate. Since leukemic cells are not sensitive
to normal regulatory mechanisms, we assume that they make their choice between self-
renewal and differentiation according to their internal properties and independently
of the surrounding cells. If this is the case, then the question is why introducing a
relatively complex hybrid model and not considering a simpler model, for example a
system of ordinary differential equations. First of all, we need to note that this should
be a cell population structured with respect to the intracellular drug concentration.
Therefore, it should be a transport equation with time dependent coefficients and
not ordinary differential equations. Second, since we introduce stochasticity in the
problem, we need to study stochastic transport equations, which are not simpler
than hybrid models. They do not admit analytical solution and should be solved
numerically. Let us finally note that in a more complete model we would need to take
into account both normal and leukemic cells, which compete for space. In this case,
introduction of space distributions would be indispensable.
The hybrid model aims at describing realistically all levels of erythropoiesis. As
more aspects of erythropoiesis get considered, such as global erythropoietin regulation
or regulation of BFU-E and CFU-E from haematopoietic stem cells, we believe the
hybrid model will be prove useful for designing biological experiments and guiding
clinical practice.
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